Morphine Sulfate Solution

Pre-Solicitation Posted

Solicitation number
SPE2D2-26-R-0017
Agency
Responses due
Not on record
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Morphine Sulfate Solution, with an anticipated solicitation release of October/November 2026. Competition is restricted to domestic sources only, meaning vendors must provide Active Pharmaceutical Ingredients and Final Dosage Forms manufactured domestically.

The procured items include Morphine Sulfate 2MG/ML and 4MG/ML Injection Syringe and 2MG/ML and 10MG/ML Intravenous Syringe in Packs of 10; and Morphine Sulfate 2MG/ML, 4MG/ML, and 10MG/ML Injection Solution Vial and 4MG/ML and 10MG/ML Intravenous Solution Vial in Boxes of 25. The contract will be firm-fixed price, requirements type with a one-year base and four one-year options. The resulting contract will establish a national supply source for purchase by Department of War, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through DLA and VA prime vendor programs, with annual usage estimates to be provided in the Schedule of Supplies section of the solicitation.

This is a commercial item procured under FAR Part 12. All qualified domestic sources may submit proposals. DLA reserves the right to issue the solicitation before or after the projected October/November 2026 date. The solicitation will be posted to the DLA Bid Board System and Sam.Gov. Contact Christopher Newman at (445) 737-7371 or Christopher.Nemwan@dla.mil for questions.

Notice text

The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Morphine Sulfate Solution. Procurement details follow.

Morphine Sulfate 2MG/ML and 4MG/ML Injection Syringe and 2MG/ML and 10MG/ML Intravenous Syringe in Packs of 10. Morphine Sulfate 2MG/ML, 4MG/ML, and 10MG/ML Injection Solution Vial and 4MG/ML and 10MG/ML Intravenous Solution Vial in Boxes of 25. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency.  

A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Christopher Newman at (445) 737-7371 or Christopher.Nemwan@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is October/November of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date.

Similar open opportunities

Opportunity Agency Set-aside Responses due
Methylphenidate ER NAICS 325412 Medical Supply Chain No set-aside
Epinephrine Injector NAICS 325412 Medical Supply Chain No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity